Home' Australian Pharmacist : Australian Pharmacist May 2016 Contents Australian Pharmacist May 2016 I ©Pharmaceutical Society of Australia Ltd.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month
(15,500 pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than
10,000 pharmacists – a typical monthly article receives 3000 plus
assessments, with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9871 5520
Ph: 0402 055 022
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Ultra-Fine Pen Needle
Becton Dickinson (BD) has announced
the release of the BD Ultra-Fine 4mm
Pen Needle with EasyFlow Technology
in Australia. With demand for more
comfortable and effective injections
increasing, BD has developed a new
pen needle featuring an extra wide
inner diameter which improves the flow
rate of injectable diabetes medication,
thereby making it easier and faster for
people with diabetes to inject their
People with diabetes recognise the
impact of BD’s latest innovation on
their injection experience, with 68%
preferring BD Ultra-Fine 4mm Pen
Needles with EasyFlow Technology.
clinical study, 61% of people reported
they needed significantly less thumb
force to inject, had greater confidence
in full dose delivery, and experienced
less skin leakage and dripping from the
BD’s new shortest, thinnest Ultra-Fine
4mm pen needle is suitable for most
people with diabetes including those
who are overweight and ensures
medication is injected to the correct
skin depth more than 99.5% of the time,
at all injection sites when used with
the appropriate injection technique.
Compared with longer pen needles, a
4mm pen needle has also been proven
to significantly lower the risk of injecting
diabetes medication into muscle at all
1. 1 . Aronson R. Diabetes Technol Ther. 2012; 14(8): 741-747 .
On 1 April, Genvoya (elvitegravir/
alafenamide), the first TAF-based once
daily single tablet regimen for the
treatment of HIV-1 infection became
available on the Pharmaceutical
Benefits Scheme (PBS) through the S100
HSD Community access scheme for
prescription by physicians specialising in
the treatment of HIV infection.
Genvoya is indicated as a single tablet
regimen for the treatment of HIV-1
infection in adults and adolescents
aged 12 years of age and older with
body weight at least 35kg who are
either treatment–naïve; or virologically
suppressed (HIV-1 RNA <50 copies/mL)
on a stable antiretroviral regimen at
start of therapy in order to replace their
current antiretroviral treatment regimen.
Patients must not have a history of
treatment failure or known mutations
associated with resistance to the
antiretroviral components of Genvoya.
The first in the next generation of
antiretroviral therapies (ARTs) known
as TAF-based regimens, Genvoya
contains tenofovir alafenamide or
TAF, a novel prodrug of the antiviral
nucleoside tenofovir (TFV). Because
TAF is more efficient than TDF in
delivering TFV into HIV-target cells, it
can be given at a lower dose, resulting
in 91% lower concentrations of TFV
in the bloodstream with similar high
antiviral efficacy and improved renal
and bone safety compared with
Genvoya’s efficacy and safety profile
is evidenced by the results of phase
3 clinical trials which enrolled over
3,500 patients in 21 countries, including
nine trial sites in Australia. The phase
3 trials included treatment-naïve
patients (Studies 104 and 111),
virologically-suppressed patients (Study
109), virologically-suppressed patients
with mild to moderate renal impairment
(Study 112) and treatment-naïve
adolescent patients (Study 112).
1. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir
alafenamide). Approved Product Information, 15 Jan 2016.
Links Archive Australian Pharmacist April 2016 Australian Pharmacist June 2016 Navigation Previous Page Next Page